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Background: Data on sexually transmitted infections (STI) prevalence among HIV-infected women in Thailand are
limited. We studied, among HIV-infected women, prevalence of STI symptoms and signs; prevalence and correlates
of having any STI; prevalence and correlates of Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (GC) among
women without CT and/or GC symptoms or signs; and number of women without CT and/or GC symptoms or
signs needed to screen (NNS) to detect one woman with CT and/or GC overall, among pregnant women, and
among women ≤25 years.
Methods: During October 2004–September 2006, HIV-infected women at 3 obstetrics and gynecology clinics were
asked about sexual behaviors and STI symptoms, physically examined, and screened for chlamydia, gonorrhea,
trichomoniasis, and syphilis. Multivariate logistic regression was used to identify correlates of infections. NNS was
calculated using standard methods.
Results: Among 1,124 women, 526 (47.0%) had STI symptoms or signs, 469 (41.7%) had CT and/or GC symptoms or
signs, and 133 (11.8%) had an STI. Correlates of having an STI included pregnancy and having STI signs. Among 469
women and 655 women with vs. without CT and/or GC symptoms or signs, respectively, 43 (9.2%) vs. 31 (4.7%), 2
(0.4%) vs. 9 (1.4%), and 45 (9.6%) vs. 38 (5.8%) had CT, GC, or “CT or GC”, respectively; correlates included receiving
care at university hospitals and having sex with a casual partner within 3 months. NNS for women overall and
women ≤25 years old were 18 (95% CI, 13-25) and 11 (95% CI, 6-23), respectively; and for pregnant and
non-pregnant women, 8 (95% CI, 4-24) and 19 (95% CI, 14-27), respectively.
Conclusions: STI prevalence among HIV-infected women, including CT and GC among those without symptoms or
signs, was substantial. Screening for CT and GC, particularly for pregnant women, should be considered.
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Sexually transmitted infections (STIs) can cause morbidity
and increase risk of HIV acquisition and transmission [1].
For those reasons, the US Centers for Diseases Control
and Prevention (CDC) recommends screening (defined as
performing tests on persons without symptoms or signs of
disease) of persons living with HIV/AIDS (PLHA) for
STIs, including syphilis, gonorrhea, chlamydia, and (for
women) trichomoniasis. Screening for those infections* Correspondence: RangsimaL@th.cdc.gov
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distribution, and reproduction in any mediumshould occur at the first visit and should be repeated peri-
odically thereafter, depending on the patient’s reported be-
haviors, the presence of STIs in the patient or the patient’s
partner(s), and the STI prevalence in the community.
HIV-care providers should also take a thorough sexual
history and perform a physical examination, including for
STIs, at the initial visit. Patients with STI symptoms or
signs should be tested and managed appropriately [2-4].
In resource-limited settings, the World Health Orga-
nization (WHO) recommends that health-care providers
obtain a thorough STI-related history from all newly diag-
nosed PLHA; conduct a physical examination to check for
STIs; and perform serologic screening for syphilis and (forCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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recommends syndromic management of patients with STI
symptoms or signs [5].
In Thailand, national guidelines recommend that pro-
viders take a history of STI symptoms and risk behavior
of PLHA receiving care at each visit; perform screening
for syphilis, but not for chlamydia and gonorrhea, at the
initial visit and annually for PLHA with sexual risk
behaviors; perform a Gram stain and bacterial culture of
cervical discharge for symptomatic HIV-infected women;
and manage STI symptoms or signs syndromically [6].
Because screening for gonorrhea and chlamydia is not
recommended in Thai national guidelines, PLHA with-
out signs or symptoms would miss an opportunity to
receive treatment that can prevent damaging sequelae of
those infections — including pelvic inflammatory dis-
ease, ectopic pregnancy, chronic pelvic pain, and infer-
tility [7,8] — and can reduce risk of STI and HIV
transmission to sex partners [1].
Limited data on STI prevalence and correlates among
HIV-infected women in Thailand are available. Such
data are necessary to guide national STI screening rec-
ommendations. Therefore, in this study, we investigated
prevalence of STI symptoms and signs; prevalence and
correlates of chlamydia and gonorrhea symptoms and
signs among HIV-infected women; prevalence and cor-
relates of having any STI among those women; preva-
lence and correlates of chlamydia or gonorrhea among
HIV-infected women without chlamydia and gonorrhea
symptoms or signs; and number of HIV-infected women
(overall, and stratified by pregnancy status and age)
without chlamydia and gonorrhea symptoms or signs
needed to screen (NNS) to detect one woman infected
with chlamydia and/or gonorrhea.
Methods
During October 2004–September 2006, we conducted
a cross-sectional study, enrolling consecutive HIV-
infected women presenting for care at 3 obstetrics and
gynecology (OB/GYN) clinics, including the university-
affiliated Siriraj and Rajavithi Hospitals in Bangkok and
the Bamrasnaradura Institute, a government-run in-
fectious diseases hospital in Nonthaburi, the province
north of Bangkok. Reasons for visiting clinics included
antenatal care (ANC), CD4+ T-lymphocyte (CD4)
monitoring and follow-up of women not eligible for
antiretroviral treatment (ART), STI symptoms, partners
of STI patients, referral from HIV clinic for Pap smear
screening and reproductive health check-up, and HIV
testing for partners of PLHA, people with sexual risk
behaviors, or people with HIV-related symptoms. Coun-
selors or nurses asked women about sexual behaviors,
including history of vaginal or anal sex during last
3 months; condom use during last vaginal or anal sex;sex with casual partners, steady partners, or sex workers
during the last 3 months; sex work during the last
3 months; and STI symptoms at time of consultation,
including vaginal or urethral discharge, dysuria, lower
abdominal pain, and genital pain or lesions. Symptoms
of chlamydia and gonorrhea included all STI symptoms
except genital pain or lesions. Data were recorded in a
standardized format in patient records.
All consenting women underwent a genital and pelvic
examination regardless of whether they reported STI
symptoms. Signs of STIs were defined as genital wart,
genital ulcer, inflamed cervix with or without pus or
blood, yellow or green or white vaginal discharge, or
adnexal or cervical motion tenderness during bimanual
examination. Signs of chlamydia and gonorrhea included
all STI signs except genital wart and ulcer.
STI treatment was done using a syndromic approach,
according to Thai national guidelines, and was provided,
along with condoms, free of charge.
Laboratory evaluation
Endocervical specimens were obtained from all women for
the detection of Chlamydia trachomatis and Neisseria
gonorrhoeae using nucleic acid hybridization test (GenProbe
Inc., San Diego, California, USA, at Siriraj and Rajavithi Hos-
pitals) and nucleic acid amplification tests (NAATs) (Cobas
Amplicor, Roche Diagnostic Systems, Basel, Switzerland, at
Bamrasnaradura Institute). Serologic tests for syphilis were
done using Rapid Plasma Reagin (RPR) card tests (New
Market Laboratory, Kentford, UK) and, for specimens
reactive on RPR testing, Treponema pallidum haemagglu-
tination assays (TPHA; Fuji-rebio, Inc., Tokyo, Japan).
Vaginal swab specimens were collected for saline wet
preparations for detection of Trichomonas vaginalis by
light microscopy.
Women were considered to have an STI if they had
clinician-diagnosed genital ulcer disease (GUD); positive
results for gonorrhea, chlamydia, or trichomoniasis; or
syphilis (defined as RPR titer positive and a reactive
TPHA test).
HIV infection status was confirmed by Murex HIV1-2
ELISA (Murex Biotech, Ltd., Dartford, UK) if not previ-
ously documented. CD4-cell count testing was performed
using a FACScan flow cytometer (Becton Dickinson
Immunocytometry Systems, San Jose, California, USA).
Pregnancy status was assessed by a urine pregnancy test.
Data on most recent CD4 count and viral load were
obtained from medical records.
Data analysis
Data were analyzed using STATA 11.0 (StataCorp., College
Station, Texas, USA). Chi-squared tests and Wilcoxon rank
sum tests were used for categorical and continuous data,
respectively. Fisher’s exact test was used for categorical
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was <5. For prevalence data, 95% confidence intervals (95%
CI) were calculated using the binomial distribution. Factors
associated with STIs and factors associated with chlamydia
or gonorrhea among HIV-infected women without chla-
mydia and gonorrhea symptoms or signs were analyzed
using bivariate and multivariate logistic regression to esti-
mate odds ratios (OR) with 95% CI. All correlates from
bivariate analysis with p <0.2 were included in a multivari-
ate model, with a backward stepwise procedure used to
include only variables with p <0.05 in the final model.
NNS was defined as the number of HIV-infected
women without chlamydia and gonorrhea symptoms or
signs who needed to be screened in order to identify one
woman with chlamydia, gonorrhea, or chlamydia and/or
gonorrhea [9]. We included the combined outcome of
chlamydia or gonorrhea because most NAATs test sim-
ultaneously for both infections. We calculated NNS as
the reciprocal of the prevalence (and 95% CIs, calculated
using exact binomial methods) of chlamydia, gonorrhea,
or chlamydia and/or gonorrhea among HIV-infected
women without symptoms or signs. We calculated NNS
for women overall, and for non-pregnant and pregnant
women specifically, since chlamydia or gonorrhea in the
latter group can be associated with additional adverse
outcomes including preterm delivery, puerperal sepsis,
and neonatal infections [7,10,11]. We also calculated
NNS for women aged >25 years and ≤25 years, because
women aged ≤25 years are at higher risk for chlamydia
and gonorrhea and CDC recommends routine screening
for chlamydia for all sexually active females aged
≤25 years [12].
This project was classified by the Thai Ministry of
Public Health and CDC as a program activity, not re-
quiring Institutional Review Board approval.
Results
Population
We enrolled 1,124 HIV-infected women, including 458
(40.7%), 300 (26.7%), and 366 (32.6%) from Siriraj Hos-
pital, Rajavithi Hospital, and Bamrasnaradura Institute,
respectively. Of those, 124 (11.0%) were pregnant, of
whom 51 (41.1%), 71 (57.3%), and 2 (1.6%) were from
Siriraj Hospital, Rajavithi Hospital, and Bamrasnaradura
Institute, respectively. Patient demographics are summa-
rized in Table 1. Median age was 32 years (interquartile
range [IQR], 28-37 years) and the median time since
learning HIV status was 3.2 years (IQR, 0.8-6.6 years).
More than 60% of women at Siriraj (280/458 [61.1%]) and
Rajavithi Hospitals (203/300 [67.7%]) presented for ANC,
postpartum follow-up, or STI symptoms, whereas two-
third (252/366 [68.9%]) of women at Bamrasnaradura
Institute were referred from HIV clinics for annualPap smear screening. Overall 521/1,124 (46.3%) were on
antiretroviral treatment (ART), including 150/458 (32.8%),
88/300 (29.3%), and 283/366 (77.3%) at Siriraj Hospital,
Rajavithi Hospital, and Bamrasnaradura Institute, respec-
tively. The median CD4 cell count overall was 292 cells/
mm3 (IQR, 140-453 cells/mm3). Among 521 women on
ART, 247 women with viral load test results available,
median viral load was <50 copies/mL (IQR, <50- < 50
copies/mL) (Table 1).Prevalence of STI symptoms and signs, prevalence and
correlates of chlamydia and gonorrhea symptoms and
signs among HIV-infected women overall
Overall prevalence of STI symptoms or signs was 526/
1,124 (47.0%, 95% CI: 43.8-49.8%) and prevalence of
chlamydia and gonorrhea symptoms or signs was 469/
1,124 (41.7%, 95% CI: 38.8-44.7%) (Table 2). Compared
with women without chlamydia and gonorrhea symp-
toms or signs, women with symptoms or signs, respect-
ively, were significantly more likely to be ≤25 years old
(20.7% vs. 12.4%; P < 0.01), have received care at
Rajavithi Hospital (48.6% vs. 11.0%; P < 0.01), had a more
recent HIV diagnosis (2.7 years vs. 3.4 years; P = 0.02),
be pregnant (17.9% vs. 6.1%; P < 0.01), had CD4 count
<200 cells/mm3 (37.5% vs. 29.5%; P < 0.01), and not be
receiving ART (53.7% vs. 41.2%; P < 0.01) (Table 1).Prevalence of STIs among HIV-infected women overall
and pregnant women and correlates of women overall
Overall among 1,124 women, 133 (11.8%, 95% CI: 10.0-
13.9%) had an STI and 106 (9.4%, 95% CI: 7.8-11.3%) had
any laboratory-diagnosed STI. STIs included 74 (6.6%,
95% CI: 5.2-8.2%) with chlamydia, 28 (2.5%, 95% CI: 1.7-
3.6%) with GUD, 17 (1.5%, 95% CI: 0.9-2.4%) with tricho-
moniasis, 11 (1.0%, 95% CI: 0.5-1.7%) with gonorrhea, and
8 (0.7%, 95% CI: 0.3-1.4%) with syphilis. Chlamydia preva-
lence was significantly lower and gonorrhea prevalence
was significantly higher, among women without chlamydia
and/or gonorrhea symptoms or signs compared with
women with symptoms or signs (Table 2).
Among 124 pregnant women, 28 (22.6%, 95% CI: 15.6-
30.9%) had an STI, including 22 (17.7%, 95% CI: 11.5-
25.6%) with chlamydia, 4 (3.2%, 95% CI: 0.9-8.0%) with
trichomoniasis, 2 (1.6%, 95% CI: 0.2-5.7%) with syphilis, 1
(0.8%, 95% CI: 0.0-4.4%) with GUD, and none with gonor-
rhea (0%, 95% CI: 0-2.9%).
In the final multivariate model, STI prevalence was
significantly higher among pregnant women (adjusted
odd ratio (aOR) 2.4, 95% CI: 1.4-3.9) and women who
had STI signs (aOR 3.3, 95% CI: 2.2-4.9) compared with
non-pregnant women and women without STI signs, re-
spectively (Table 3).
Table 1 Characteristics of HIV-infected women at three clinics in Thailand, according to presence or absence of
chlamydia and/or gonorrhea symptoms or signs
Characteristics Number (%) of
women
Number with chlamydia or
gonorrhea symptoms/signs*
Number without chlamydia or
gonorrhea symptoms/signs*
P-value
(N = 1,124) (n = 469, 41.7%) (95 % CI: 38.8-44.7) (n = 655, 58.3%) (95% CI: 55.3-61.2)
Demographic characteristics
Age, years (median (IQR)) 32 (28-37) 31 (26-35) 33 (29-38) <0.01
≤25 178 (15.8) 97 (20.7) 81 (12.4)
>25 944 (84.0) 372 (79.3) 572 (87.3)
Missing 2 (0.2) 0 (0.0) 2 (0.3)
Hospital
Siriraj Hospital 458 (40.7) 153 (32.6) 305 (46.6) <0.01
Rajavithi Hospital 300 (26.7) 228 (48.6) 72 (11.0) <0.01
Bamrasnaradura Institute 366 (32.6) 88 (18.8) 278 (42.4) <0.01
Highest level of education, years
(median (IQR))
9 (6-12) 7 (6-12) 9 (6-12) 0.30
≤ Grade 6 530 (47.1) 229 (48.8) 301 (46.0)
> Grade 6 593 (52.8) 240 (51.2) 353 (53.9)
Missing 1 (0.1) 0 (0.0) 1 (0.1)
Years since HIV diagnosis (median
(IQR))
3.2 (0.8-6.6 years) 2.7 (0.5-5.8 years) 3.4 (1.1-7.4 years) 0.02
Cause of HIV infection
Heterosexual 1025 (91.2) 427 (91.0) 598 (91.3) 0.88
Other 99 (8.8) 42 (9.0) 57 (8.7)
Pregnancy
Yes 124 (11.0) 84 (17.9) 40 (6.1) <0.01
Clinical characteristics
Most recent CD4 count (cells/mm3)
(median (IQR)) 292 (140-453) 265 (110-438) 340 (160-460) 0.02
≤ 200 369 (32.8) 176 (37.5) 193 (29.5) <0.01
> 200 744 (66.2) 285 (61.8) 459 (70.0)
Unknown or missing 11 (1.0) 8 (1.7) 3 (0.5)
Most recent HIV viral load: HIV-1 RNA
(copies/mL) median (IQR)
<50 (<50- < 50) <50 (<50- < 50) <50 (<50- < 50)
≤ 50 178 (15.8) 37 (7.9) 141 (21.5) <0.01
> 50 69 (6.2) 33 (7.0) 36 (5.5)
Missing 877 (78.0) 399 (85.1) 478 (73.0)
Currently on antiretroviral treatment
No 522 (46.4) 252 (53.7) 270 (41.2) <0.01
Yes 521 (46.4) 171 (36.5) 350 (53.5)
Unknown or missing 81 (7.2) 46 (9.8) 35 (5.3)
Behaviors in last 3 months
Sex in the last 3 months1 722 (64.2) 316 (67.4) 406 (62.0) 0.06
• Had steady partner2
Yes 622 (86.2) 277 (87.6) 345 (85.0) 0.30
Condom at last sex 66.7% 59.3% 73.0%
No 66 (9.1) 28 (8.9) 38 (9.3)
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Table 1 Characteristics of HIV-infected women at three clinics in Thailand, according to presence or absence of
chlamydia and/or gonorrhea symptoms or signs (Continued)
Missing 34 (4.7) 11 (3.5) 23 (5.7)
• Had casual partner 3
Yes 29 (4.0) 12 (3.8) 17 (4.2) 0.79
Condom at last sex 56.0% 33.3% 76.9%
No 639 (88.5) 291 (92.1) 348 (85.7)
Missing 54 (7.5) 13 (4.1) 41 (10.1)
1 Vaginal and/or anal sex.
2 Steady partner was defined as a person the woman has known for more than 2 months, with whom she has regular sex and to whom she feels
psychologically connected.
3 Casual partner was defined as a person the woman has sex with and who do not meet the definition of CSW or steady partner.
*Chlamydia and gonorrhea symptoms or signs were defined as STI symptoms or signs except genital wart, genital ulcer, genital lesions.
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among women with and without chlamydia and
gonorrhea symptoms or signs
Among 469 women and 655 women with vs. without
symptoms or signs, respectively, 58 (12.4%, 95% CI: 9.5-
15.7) vs. 48 (7.3%, 95% CI: 5.4-9.6) had a laboratory-
diagnosed STI, including 43 (9.2 %) vs. 31 (4.7%) with
chlamydia and 2 (0.4%) vs. 9 (1.4%) with gonorrhea
(Table 2). In the final multivariate model, chlamydia
and/or gonorrhea prevalence was significantly higher
among women receiving care at Siriraj Hospital (aOR
12.1, 95% CI: 2.8-52.0) or Rajavithi Hospital (aOR 20.3,Table 2 Prevalence of STIs among HIV-infected women with a
Laboratory-diagnosed sexually
transmitted infections
Number (%, 95% CI) of
women (N = 1,124)
Numb
chlam
s
(n = 4
Chlamydia 74 (6.6; 5.2-8.2)
Gonorrhea 11 (1.0; 0.5-1.7)
Syphilis 8 (0.7; 0.3-1.4)
Trichomoniasis 17 (1.5; 0.9-2.4)
Any laboratory-diagnosed STI 1 106 (9.4; 7.8-11.3) 5
Sexually transmitted infections Number (%; 95% CI) of
women (N = 1,124)
Numb
s
(n = 5
Genital ulcer disease 28 (2.5; 1.7-3.6)
Chlamydia 74 (6.6; 5.2-8.2)
Gonorrhea 11 (1.0; 0.5-1.7)
Syphilis 8 (0.7; 0.3-1.4)
Trichomoniasis 17 (1.5; 0.9-2.4)
Any STI2 133 (11.8; 10.0-13.9) 9
1 Gonorrhea by NAAT/Chlamydia by NAAT/Trichomoniasis by wet mount/laboratory
2 Gonorrhea by NAAT/Chlamydia by NAAT/Trichomoniasis by wet mount /laborator
#STI symptoms or signs were defined as symptomatic vaginal discharge, urethral di
blood or other) or vaginal discharge on examination (white/yellow/green/other) or
genital ulcer, genital lesions.
*Chlamydia and gonorrhea symptoms or signs were defined as STI symptoms or sig95% CI: 4.2-98.4), compared with women receiving care
at Bamrasnaradura Institute; and among women having
≥1 casual partner during last 3 months (aOR 6.3, 95%
CI: 1.6-24.7), compared with women having no casual
partners during the last 3 months (Table 4).
Number needed to screen
Overall the NNS to detect one woman infected with
chlamydia, gonorrhea, or chlamydia and/or gonorrhea
were 22 (95% CI, 16-31), 73 (95% CI, 39-159), and 18
(95% CI, 13-25), respectively. NNS for women ≤25 years
vs. >25 years for chlamydia, gonorrhea, or chlamydiand without STI symptoms or signs
er (%; 95% CI) with Number (%; 95% CI) without P-value
ydia or gonorrhea
ymptoms/signs*
chlamydia or gonorrhea
symptoms/signs*
69) (41.7; 38.8-44.7) (n = 655) (58.3; 55.3-61.2)
43 (9.2; 6.7-12.1) 31 (4.7; 3.2-6.6) <0.01
2 (0.4; 0.0-1.5) 9 (1.4; 0.6-2.6) <0.01
3 (0.6; 0.1-1.9) 5 (0.8; 0.2-1.8) 0.83
11 (2.3; 1.2-4.1) 6 (0.9; 0.3-2.0) 0.05
8 (12.4; 9.5-15.7) 48 (7.3; 5.4-9.6 ) <0.01
er (%; 95% CI) with
STI
Number (%; 95% CI) without
STI
P-value
ymptoms/signs# symptoms/signs#
26) (47.0; 43.8-49.8) (n = 598) (53.0; 50.2-56.1)
28 (5.3; 3.6-7.6) 0 (0.0; 0.0-0.6) <0.001
47 (8.9; 6.6-11.7) 27 (4.5; 3.0-6.5) <0.01
3 (0.6; 0.1-1.7) 8 (1.3; 0.6-2.6) 0.19
3 (0.6; 0.1-1.7) 5 (0.8; 0.3-1.9) 0.60
12 (2.3;1.2-3.9) 5 (0.8; 0.3-1.9) 0.05
0 (17.1; 14.0-24.6) 43 (7.2;5.2-9.6 ) <0.001
confirmed syphilis.
y confirmed syphilis/genital ulcer or GUD.
scharge, or lower abdominal pain or cervix examination (inflammation/pus/
cervical motion tenderness during bimanual examination or genital wart,
ns except genital wart, genital ulcer, genital lesions.
Table 3 Factors associated with sexually transmitted infections among HIV-infected women at three clinics, Thailand
(N = 1,124)
Predictors STI 1 (No., %) OR (95% CI) P value Adjusted ORd
(95% CI)
P value
Yes (n = 133) No (n = 991)
Age
≤ 25 yrs 30 (16.9) 148 (83.1) 1.7 (1.0, 2.6) 0.03 -
> 25 yrs 103 (10.9) 841 (89.1) 1 -
Years of education
≤ Grade 6 62 (11.7) 468 (88.3) 1.0 (0.77, 1.4) 0.96
> Grade 6 71 (12.0) 522 (88.0) 1
Hospital
Siriraj 59 (12.9) 399 (87.1) 2.1 (1.2, 3.6) <0.01 -
Rajavithi 50 (16.7) 250 (83.3) 2.8 (1.7, 4.9) <0.01 -
Bamrasnaradura 24 (6.6) 342 (93.4) 1 -
Pregnancy
Yes 28 (22.6) 96 (77.4) 2.5 (1.5, 4.1) <0.01 2.4 (1.4, 3.9) 0.001
No 105 (10.5) 895 (89.5) 1 1
Sex work
Previous/ current 9 (16.7) 45 (83.3) 1.4 (0.6, 3.2) 0.44
Never 115 (12.2) 831 (87.8) 1
Casual partner last 3 months
Yes 6 (17.6) 28 (82.4) 1.5 (0.5, 3.8) c 0.43 f
No 119 (12.5) 833 (87.5) 1
Steady partner last 3 months
Yes 78 (11.9) 580 (88.1) 0.8 (0.6, 1.3) 0.43
No 48 (13.8) 300 (86.2) 1
Condom use last 3 months
No 31 (13.4) 201 (86.6) 1.0 (0.6, 1.6) 0.92 -
Yes 48 (9.8) 442 (90.2) 0.7 (0.4, 1.1) 0.11 -
No sex last
3 months
54 (13.4) 348 (86.6) 1 -
Time after infection
< 6 months 31 (15.4) 170 (84.6) 1.4 (0.9, 2.3) 0.12 -
≥ 6 months 98 (11.2) 780 (88.8) 1 -
Latest CD4 count
0-200 cells/mm3 51 (13.8) 318 (86.2) 1.3 (0.9, 1.9) 0.21
> 200 cells/mm3 82 (11.0) 662 (89.0) 1
Abnormal symptom 2
≥ 1 symptom(s) 61 (17.3) 292 (82.7) 2.0 (1.4, 3.0) <0.01 -
None 72 (9.3) 699 (90.7) 1 -
STI signs 3
≥ 1 sign(s) 73 (21.5) 266 (78.5) 3.3 (2.3, 4.9) <0.001 3.3 (2.2, 4.9) <0.001
None 60 (7.6) 725(92.4) 1 1
Latest viral load
<50 copies/ml 9 (5.1) 169 (94.9) 0.9 (0.2, 4.0) c 0.76 f
≥50 copies/ml 4 (5.8) 65 (94.2) 1
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Table 3 Factors associated with sexually transmitted infections among HIV-infected women at three clinics, Thailand
(N = 1,124) (Continued)
Current ARV
No 72 (13.8) 450 (86.2) 1.5 (1.0, 2.2) 0.04 -
Yes 50 (9.6) 471 (90.4) 1 -
f Fisher Exact test.
c Exact Confidence Limits.
d Adjusted for age, hospital, pregnancy, condom use last 3 months, time after infection, abnormal symptoms, STI signs, and current ARV treatment.
1 Gonorrhea by PCR/Chlamydia by PCR/Trichomoniasis by wet mount /GUD by doctor conclusion/laboratory confirmed syphilis (VDRL/TPHA).
2 Genital pain/ genital lesion/ vaginal discharge/urethral discharge/ lower abdominal pain.
3 Genital wart/genital ulcer/abnormal cervix/abnormal vaginal discharge/cervical motion tenderness during bimanual examination.
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CI, 16-34), 28 (95% CI, 10-130) vs. 96 (95% CI, 45-260),
and 11 (95% CI, 6-23) vs. 20 (95% CI, 14-29), respect-
ively (Figure 1).
Among pregnant women, the NNS for chlamydia was
8 (95% CI, 4-24). Because no pregnant women had
gonorrhea, NNS for gonorrhea could not be calculated
(infinity) and the NNS for chlamydia or gonorrhea was
equal to that for chlamydia alone. Among non-pregnant
women, the NNS for chlamydia and/or gonorrhea was
19 (95% CI, 14-27), 11 (95% CI: 6-30), and 21 (95% CI:
15-31) for overall women, aged ≤25, and >25 years, re-
spectively (Figure 2).
Discussion
Substantial STI rate and low rate of condom use among
HIV-infected women from our study highlighted the
need for assessment of sexual risk behavior and STI
symptoms or signs, particularly pregnant women at each
clinical visit in order to identify women with risk for STI
and provide appropriate evaluation and treatment. STIs
in HIV-infected women when untreated may facilitate
STI and HIV transmission to unprotected sex partners,
contributing to new HIV and STI infections. Therefore,
prevention with positives services should be emphasized
and incorporated in routine service [2].
Although some studies in Europe and the U.S. have
shown a low prevalence (≤5%) of STI among HIV-
infected women [13-15], our study showed that STI
prevalence among HIV-infected women (11.8%, 95% CI:
10.0-13.9%) was in the same range of many reports of
HIV-infected women in Thailand and elsewhere (7-20%)
[16-19]. Overall STI prevalence in women with STI
symptoms or signs was higher than the prevalence in
women without symptoms or signs. Although Thailand’s
national HIV treatment and care guidelines recommend
that providers take a history of STI symptoms and risk
behavior at each visit and perform a Gram stain and cul-
ture of cervical discharge for symptomatic HIV-infected
women, this study and other reports on HIV-infected
women [20,21] and pregnant women [22] showed that
some STIs including chlamydia, gonorrhea, trichomo-
nas, and syphilis, can have no symptoms or signs. Usingsymptomatic screening for STI may not be sensitive
enough to detect an STI among HIV-infected women. In
contrast, women with STI symptoms or signs might not
have an STI, since many of those symptoms and signs are
not STI-specific. Therefore, clinicians should be aware
that a recommendation for syndromic management for
STIs among these women might lead to overtreatment.
Simple and affordable STI diagnostic tests should be
developed for use in routine STI screening of these
women.
The overall chlamydia and gonorrhea prevalence
among HIV-infected women in this study (6.6% and
1.0%, respectively) was not substantially different from
the previous report of chlamydia and gonorrhea preva-
lence in HIV-uninfected Thai youth aged 15-21 years
old (5% and 0.4%, respectively) [23]. Chlamydia preva-
lence among HIV-infected women without symptoms or
signs in our study was lower than HIV-infected women
with symptoms or signs 4.7% (95% CI: 3.2-6.6%) vs. 9.2%
(95% CI: 6.7-12.1%). In this study, gonorrhea prevalence
was higher among HIV-infected women without symp-
toms or signs (1.4%, 95% CI: 0.6-2.6%) than those with
symptoms or signs (0.4%, 95% CI: 0-1.5%), in line with a
report on gonorrhea in HIV-uninfected women [20].
This finding echoes those above that some STIs can
present without symptoms and signs.
Chlamydia and gonorrhea prevalence among HIV-
infected women without symptoms or signs receiving care
at Bamrasnaradura Institute was significantly lower than
chlamydia and gonorrhea prevalence among women
receiving care at Siriraj or Rajavithi Hospitals. This may be
due to the fact that the women receiving care at the 3
hospitals were from different population and may have
had different expected risk for STIs. Almost 70% of
women receiving care at Bamrasnaradura Institute’s clinic
were referred there from HIV clinics for annual Pap smear
and STI screening, including for chlamydia and gonor-
rhea, as part of an HIV quality improvement project [24].
So some HIV-infected women at Bamrasnaradura Insti-
tute were likely treated in the previous year for STIs
detected prior to presentation at this visit. By contrast,
Siriraj and Rajavithi Hospitals did not participate in the
HIV quality improvement project.
Table 4 Factors associated with Chlamydia and/or Gonorrhea among HIV-infected women without chlamydia and
gonorrhea symptoms and/or signs (N = 655)
Characteristics Chlamydia and/or Gonorrhea (No., %) OR (95% CI) P
value
Adjusted
ORd (95% CI)
P value
Yes (n = 38) No (n = 617)
Age
≤25 yrs 8 (9.9) 73 (90.1) 2.0 (0.8, 4.7) c 0.12 f
>25 yrs 30 (5.2) 542 (94.8) 1
Years of education
≤ Primary school 19 (6.3) 282 (93.7) 1.2 (0.6, 2.4) 0.73
> Primary school 19 (5.4) 334 (94.6) 1
Clinic
Siriraj Hospital 26 (8.5) 279 (91.5) 12.9 (3.2, 112.5) <0.01 12.1 (2.8, 52.0) <0.01
Rajavithi Hospital 10 (13.9) 62 (86.1) 22.3 (4.5, 211.3) <0.01 20.3 (4.2, 98.4) <0.01
Bamrasnaradura Institute 2 (0.7) 276 (99.3) 1 1
Pregnancy
Yes 5 (12.5) 35 (87.5) 2.5 (0.7, 7.1) c 0.07 f -
No 33 (5.4) 582 (94.6) 1
Sex work
Previous/current1 4 (13.3) 26 (86.7) 2.4 (0.6, 7.6) c 0.12 f -
Never 32 (6.0) 503 (94.0) 1
Casual partner last 3 months2
Yes 3 (13.6) 19 (86.4) 2.4 (0.4, 8.7) c 0.17 f 6.3 (1.6, 24.7) 0.01
No 33 (6.2) 498 (93.8) 1
Steady partner last 3 months3
Yes 21 (5.8) 339 (94.2) 0.7 (0.4, 1.6) 0.52
No 16 (7.6) 195 (92.4) 1
Condom use last 3 months4
No 10 (8.8) 103 (91.1) 1.6 (0.6, 4.1) 0.36
Yes 14 (4.8) 279 (95.2) 0.8 (0.4, 1.9) 0.80
No sex last 3 months 14 (5.6) 235 (94.4) 1
Time after infection
< 6 months 5 (5.3) 90 (94.7) 0.9 (0.3, 2.3) c 0.97
≥ 6 months 32 (6.0) 503 (94.0) 1
Latest CD4 count
0-200 cells/mm3 10 (5.2) 183 (94.8) 0.8 (0.4, 1.8) 0.78
> 200 cells/mm3 28 (6.1) 431 (93.9) 1
Latest viral load
≤50 copies/mL 9 (5.1) 169 (94.9) 0.9 (0.2, 4.0) c 0.76 f
> 50 copies/mL 4 (5.8) 65 (94.2) 1
Current ARV
No 21 (7.8) 249 (92.2) 2.0 (1.0, 4.3) 0.07 -
Yes 14 (4.0) 336 (96.0) 1
f Fisher Exact test.
c Exact Confidence Limits.
d Adjusted for clinic, pregnancy, sex work history, casual partner last 3 months, and current ARV treatment.
1 Current refer to sex work during last 3 months, Previous = Ever had sex work in the past but not practicing sex work during last 3 months.
2 Casual partner refer to a person that has sex with but do not fit in the definition of CSW nor steady partner.
3 Steady partner refer to a person that has been known for more than 2 months, having regular sex and feel psychological connected.
4 Vaginal and/or anal sex.
Denominator may vary due to missing data.
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Diagnosis No sign 
and/or 
symptoms±
Number with 
infection
Number 
without 
infection
Number needed to 
screen to detect 
one woman with 
infection
95% CI#
Chlamydia
All ages 31 624 22 16, 31
≤ 25 yrs 5 76 17 9, 108
> 25 yrs 26 546 23 16, 34
Missing 0 2 2, 
Gonorrhea
All ages 9 646 73 39, 159
≤ 25 yrs 3 78 28 10, 130
> 25 yrs 6 566 96 45, 260
Missing 0 2 2, 
Chlamydia or 
Gonorrhea*
All ages 38 617 18 13, 25
≤ 25 yrs 8 73 11 6, 23
> 25 yrs 30 542 20 14, 29
Missing 0 2 2, 
± Any of symptomatic vaginal discharge, urethral discharge, or lower abdominal pain or cervix 
examination (inflammation/pus/swab pus/blood or other) or vaginal discharge examination 
(white/yellow/green/other) or cervical motion tenderness during bimanual examination. 
* 2/655 positive for both chlamydia and gonorrhea. 
: infinity. 
# 95% exact binomial confidence interval. 
Figure 1 Number of HIV-infected women without chlamydia and gonorrhea symptoms or signs needed to screen to detect one
woman with chlamydia, gonorrhea, or chlamydia or gonorrhea at three clinics in Thailand (N = 655).
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http://www.biomedcentral.com/1471-2458/13/373Women without signs or symptoms who had sex with
casual partners in the last three months were more likely
to have chlamydia or gonorrhea than those who did not.
This may be due to only half of these women reporting
using condoms at last sex with casual partners.
In this study, pregnancy was associated with increased
overall risk of STI. Having an STI during pregnancy can
threaten the pregnancy and unborn baby’s health; some
STIs can cross the placenta and infect the fetus or pass
though the birth canal to cause peripartum infection
[10,11]. The overall chlamydia prevalence among HIV-
infected pregnant women was high (18%, 95% CI: 11.5-
25.6%) and in line with a report on HIV-infected pregnant
women in Thailand in 1997 (16%) [25]. The chlamydia
prevalence in HIV-infected pregnant women was also
higher than the prevalence among HIV-uninfected
pregnant women in previous report in Thailand (9%) [25].
The low prevalence of gonorrhea is consistent with prior
reports. No gonorrhea cases (0%, 95% CI: 0-2.9%) weredetected among pregnant women in this study compared
to previous reports of gonorrhea prevalence in HIV-
infected pregnant women (2.7%) and HIV-uninfected
pregnant women in Thailand (1.4%) [25].
This study showed that screening for chlamydia and
gonorrhea for HIV-infected women without STI symp-
toms or signs can detect additional cases. NNS can be one
of the metrics used to evaluate the cost-effectiveness of a
potential or existing screening program. In this study,
NNS for HIV-infected women, non-pregnant women, and
pregnant women without STI symptoms or signs of
chlamydia or gonorrhea was 18, 19, and 8, respectively.
Because of additional potential benefits to the fetus, HIV-
infected pregnant women might be the subgroup that
benefits most from screening. For non-pregnant women,
NNS for women aged ≤25 and >25 were 11 and 21, re-
spectively. HIV-infected non pregnant women aged
≤25 years who have unprotected sex may be the subgroup
that benefits second-most from screening.
Diagnosis No sign 
and/or 
symptoms±
Number with 
infection
Number 
without 
infection
Number needed to 
screen to detect 
one woman with 
infection
95% CI#
Pregnant women
Chlamydia
All ages 5 35 8 4, 24
≤25 yrs 2 13 8 3, 61
>25 yrs 3 22 9 4, 40
Gonorrhea
All ages 0 40 12, 
≤25 yrs 0 15 5,
>25 yrs 0 25 8,
Chlamydia or 
gonorrhea
All ages 5 35 8 4, 24
≤25 yrs 2 13 8 3, 61
>25 yrs 3 22 9 4, 40
Non pregnant women
Chlamydia
All ages 26 589 24 17, 36
≤ 25 yrs 3 63 23 8, 106
> 25 yrs 23 524 24 17, 38
Gonorrhea
All ages 9 606 69 37, 149
≤ 25 yrs 3 63 23 8, 106
> 25 yrs 6 541 92 43, 248
Chlamydia or 
gonorrhea
All ages 33 582 19 14, 27
≤ 25 yrs 6 60 11 6, 30
> 25 yrs 27 520 21 15, 31
± Any of symptomatic vaginal discharge, urethral discharge, or lower abdominal pain or cervix 
examination (inflammation /pus/swab pus/blood or other) or vaginal discharge examination (white
/yellow/green/other) or cervical motion tenderness during bimanual examination.
: infinity.
# 95% exact binomial confidence interval.
Figure 2 Number of HIV-infected pregnant and non pregnant women without chlamydia and gonorrhea symptoms or signs needed to
screen to detect one woman with chlamydia, gonorrhea, or chlamydia or gonorrhea at three clinics in Thailand.
Asavapiriyanont et al. BMC Public Health 2013, 13:373 Page 10 of 12
http://www.biomedcentral.com/1471-2458/13/373Our study is one of a few studies in Thailand that
reported STI prevalence among HIV-infected women
[17,25-27]. It is the first study to report NNS among HIV-
infected women and HIV-infected pregnant women in
Thailand without STI signs and symptoms. This study hasat least four limitations. First, the data are from 2004-2006
and might not represent the current situation, in which
ART has become more available and prevention with
positives programs have been recommended as standards
[28]. Second, the data are limited to only HIV-infected
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Nonthaburi and might not be generalizable to other treat-
ment settings or geographic areas in Thailand. Third, we
did not collect data for the total number of women who
were approached to participate in this project. Study
nurses estimated that 10-20% of approached women de-
clined to participate because of they were uncomfortable
talking about STIs or believed they did not have an STI
because they were asymptomatic and/or on ART. Finally,
we did not collect data on other STIs (e.g. herpes simplex
virus infection, hepatitis B virus infection), and bacterial
culture from women with STI symptoms or signs for con-
firmation of laboratory-diagnosed STIs.
Conclusions
Overall STI prevalence among HIV-infected women seen
at three OB/GYN clinics in Thailand during 2004-2006
was 11.8%. Clinicians should be aware of high rates of
STIs, particularly among pregnant women and women
with STI symptoms or signs. Using STI symptomatic
screening and syndromic management alone might result
in missed opportunities to detect STIs and to over-
treatment of STI-uninfected women. Based on findings
from this study, chlamydia and gonorrhea screening for
HIV-infected women, including pregnant women, can
detect additional STIs. In order to evaluate the utility of
screening for chlamydia and gonorrhea among HIV-
infected women, more studies are needed regarding the
cost-effectiveness of such screening, including projected
screening costs and benefits.
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